Latest Health News

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Ardiden Limited advances exploration at its Pickle Lake Gold Project in Northwest Ontario, focusing on high-potential prospects while maintaining a robust financial position with A$11.4 million in cash and no debt.

Openn Negotiation Ltd has reported a remarkable financial turnaround in its half-year results to December 2024, shifting from a significant loss to a modest profit while divesting key subsidiaries.

Aeris Environmental reported a robust 62% revenue increase in the June 2025 quarter, driven by new international contracts and expanding adoption of its Syncromesh IoT platform.

Orpheus Uranium Limited reported a net cash outflow from operations and investing in the June quarter but strengthened its cash position through financing activities, extending its funding runway to over seven quarters.

Opyl Limited has secured three key partnerships validating its AI-driven TrialKey platform, completed a strategic review to boost AI capabilities, and strengthened its balance sheet with a $1.5 million capital raise and Bitcoin investment.

Jatcorp Limited reported a robust 76% revenue increase in Q4 FY25, driven by strong Moroka® sales and expanded manufacturing capabilities, setting ambitious growth targets for FY26.

Magnis Energy Technologies progresses detailed engineering on its Nachu Graphite Project and moves to fast track US anode material production, while navigating ASX suspension and IM3NY bankruptcy fallout.

Nickel Industries reported record ore sales and EBITDA at its Hengjaya Mine for the June 2025 quarter, alongside significant progress on key projects and sustainability initiatives.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

NGX Limited progresses its Malingunde graphite project with technical studies and stakeholder engagement, while uranium exploration permits advance in Namibia. The company stands to benefit from new US anti-dumping tariffs on Chinese graphite imports.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.